fapi-46 precursor is supplied in single use vials (0.050 mg ± 20%) from abx (advanced biochemical compounds gmbh, germany) in powder form.  (ABX advanced biochemical compounds GmbH)

Journal: Pharmaceuticals

Article Title: Bridging Research and Clinical Practice: Automated [ 68 Ga]Ga-FAPi-46 Synthesis and Quality Control for Oncological PET Imaging

doi: 10.3390/ph19040594

Figure Lengend Snippet: Radiochemical stability assessment of [ 68 Ga]Ga-FAPi-46 in ( A ) saline solution (room temperature) and ( B ) human serum (37 °C), assessed through ascending chromatography. Data are expressed as ‘mean ± SD’ ( n = 3–4). No statistically significant difference was observed within the time interval for the radiochemical stability in saline solution ( p = 0.1758) and human serum ( p = 0.8388). ANOVA was conducted, followed by Tukey’s multiple comparisons test.

Article Snippet: The precursor FAPi-46 was obtained from MedChemExpress (Monmouth Junction, NJ, USA), and radiolabeling was performed using an automated synthesis module (Lab PharmTracer, Eckert & Ziegler, Berlin, Germany) ( ).

Techniques: Saline, Chromatography

Journal: Pharmaceuticals

Article Title: Bridging Research and Clinical Practice: Automated [ 68 Ga]Ga-FAPi-46 Synthesis and Quality Control for Oncological PET Imaging

doi: 10.3390/ph19040594

Figure Lengend Snippet: RP-HPLC chromatographic profiles: ( A ) Free [ 68 Ga]GaCl 3 and the unlabeled FAPi-46 precursor; ( B ) [ 68 Ga]Ga-FAPi-46 evaluated at different time points after radiolabeling (radiochemical stability).

Article Snippet: The precursor FAPi-46 was obtained from MedChemExpress (Monmouth Junction, NJ, USA), and radiolabeling was performed using an automated synthesis module (Lab PharmTracer, Eckert & Ziegler, Berlin, Germany) ( ).

Techniques: Radioactivity

Journal: Pharmaceuticals

Article Title: Bridging Research and Clinical Practice: Automated [ 68 Ga]Ga-FAPi-46 Synthesis and Quality Control for Oncological PET Imaging

doi: 10.3390/ph19040594

Figure Lengend Snippet: [ 68 Ga]Ga-FAPi-46 and [ 18 F]FDG PET/CT of a 50-year-old woman with lung adenocarcinoma for initial staging. ( A – G ): [ 68 Ga]Ga-FAPi-46 PET/CT. ( H – N ): [ 18 F]FDG PET/CT. ( A , H ): Maximum intensity projection (anterior view). ( D – G ): [ 68 Ga]Ga-FAPi-46 PET/CT and ( K – N ): [ 18 F]FDG PET/CT axial fusion images. PET/CT shows intense uptake of both ( E ) [ 68 Ga]Ga-FAPi-46 and ( L ) [ 18 F]FDG in the primary tumor in the right lung (green arrows). Tracer uptake is also observed in ipsilateral pulmonary hilum and subcarinal lymph nodes metastases (pink circles and arrows) and in a right supraclavicular lymph node metastasis (yellow arrow). Of note, PET/CT with [ 68 Ga]Ga-FAPi-46 showed greater degree of uptake in mediastinal and supraclavicular lymph nodes ( F , G , D ) in comparison to [ 18 F]FDG ( M , N , K ). A nodular lesion in central nervous system shown on head MRI (( J ), red arrow) is shown on PET/CT with [ 68 Ga]Ga-FAPi-46 (( B , C ), red arrows) but is not identified on [ 18 F]FDG PET/CT ( I ). Thyroid uptake due to thyroiditis (blue arrow) is observed in [ 18 F]FDG PET/CT ( K ) but not in [ 68 Ga]Ga-FAPi-46 images ( D ).

Article Snippet: The precursor FAPi-46 was obtained from MedChemExpress (Monmouth Junction, NJ, USA), and radiolabeling was performed using an automated synthesis module (Lab PharmTracer, Eckert & Ziegler, Berlin, Germany) ( ).

Techniques: Positron Emission Tomography-Computed Tomography, Comparison

Journal: Pharmaceuticals

Article Title: Bridging Research and Clinical Practice: Automated [ 68 Ga]Ga-FAPi-46 Synthesis and Quality Control for Oncological PET Imaging

doi: 10.3390/ph19040594

Figure Lengend Snippet: Schematic representation of the automated synthesis and purification process for [ 68 Ga]Ga-FAPi-46. Adapted from NIAID NIH BioArt Source .

Article Snippet: The precursor FAPi-46 was obtained from MedChemExpress (Monmouth Junction, NJ, USA), and radiolabeling was performed using an automated synthesis module (Lab PharmTracer, Eckert & Ziegler, Berlin, Germany) ( ).

Techniques: Purification

Journal: Theranostics

Article Title: Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics

doi: 10.7150/thno.125403

Figure Lengend Snippet: Representative chemical structures and functional groups of (A) FAPI-04, (B) FAPI-46, and (C) Alb-FAPtp-01 and (D) the developed peptide tracer (Alb-FAPtp-02). (E) FAP expression level in U-87MG and HEK293T. (F) Cellular uptake of ⁶⁸Ga-FAPI-04, ⁶⁸Ga-FAPI-46, and ⁶⁸Ga-Alb-FAPtp-02 in U-87 MG and HEK293T cells. No significant. (G) Competitive binding assay showing inhibition of tracer uptake in U-87 MG cells by non-radiolabeled FAPI-04, confirming FAP-specific binding (n = 3, mean ± s.d.). ( H ) In vivo dynamic PET imaging analysis comparison of FAP tracers. Representative dynamic PET/CT imaging of ⁶⁸Ga-Alb-FAPtp-02, ⁶⁸Ga-FAPI-46 and ⁶⁸Ga-FAPI-04 in mice with glioma xenografts. (I) the corresponding time-activity curves of radiotracers for U-87 MG tumors and muscle. Statistical significance was determined using one-way ANOVA followed by Tukey's HSD post hoc test. * p < 0.05.

Article Snippet: The FAPI-04 precursor was sourced from KriSan Biotech Co. (Tainan, Taiwan), a PICS/GMP-compliant pharmaceutical manufacturer, whereas the FAPI-46 precursor was purchased from MedChemExpress (MCE, New Jersey, USA).

Techniques: Functional Assay, Expressing, Competitive Binding Assay, Inhibition, Binding Assay, In Vivo, Imaging, Comparison, Positron Emission Tomography-Computed Tomography, Activity Assay